ReviewLife (Basel, Switzerland)2023
Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy.
Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 39 citations in OpenAlex.
- Trial
- Observational
- Body composition's effect on the bone-vascular axis of osteoporosis discovered in AI-based CT analysis of COPD patients.European radiology · 2026Observational
- Article
- Cardiovascular Risk During the 90-Day Vulnerable Window After COPD Exacerbations: A Narrative Review.Life (Basel, Switzerland) · 2026Review
- Chronic Obstructive Pulmonary Disease as an Independent Predictor of Left Main Coronary Artery Disease.Medical sciences (Basel, Switzerland) · 2026Article
- The role of COPD and inhaled corticosteroids in major adverse cardiovascular events in cardiovascular-kidney-metabolic populations.BMC medicine · 2026Article
- Undiagnosed Coronary Artery Disease in Patients with COPD.Journal of clinical medicine · 2026Article
- Identification of Clinically Distinct Clusters in Patients With Severe COPD Using Circulating Blood Cell Population Parameters.Respirology (Carlton, Vic.) · 2026Article
- AI enhancing differential diagnosis of acute chronic obstructive pulmonary disease and acute heart failure.iScience · 2026Article
- A deep dive into atrial fibrillation in chronic obstructive pulmonary disease.NPJ primary care respiratory medicine · 2026Review
- Association of Cardiovascular Disease and Its Subtypes with Prognosis in Hospitalized Patients with AECOPD: A Retrospective Cohort Study.International journal of chronic obstructive pulmonary disease · 2026Article
- Integrating Disease Burden and Cost-Effectiveness for Value-Based Prioritisation of COPD Interventions: A Narrative Review.International journal of chronic obstructive pulmonary disease · 2026Review
- The Disproportionate Burden of Cardiovascular Disease in Mild-to-Moderate COPD.International journal of chronic obstructive pulmonary disease · 2026Article
- A Proposed Checklist for Optimizing COPD Patient Discharge Processes in Italian Internal Medicine Wards.International journal of chronic obstructive pulmonary disease · 2026Review
- Association of C-Reactive Protein-Triglyceride Glucose Index With Chronic Obstructive Pulmonary Disease: Results From the NHANES and CHARLS Cohorts.Mediators of inflammation · 2026Article
- Temporal trends in stroke-prevention medication use in patients with atrial fibrillation and chronic obstructive pulmonary disease.Frontiers in pharmacology · 2026Article
- COPD and Cardiovascular Diseases: Biomarker-Guided Stratification and Therapeutic Perspectives.Journal of clinical medicine · 2025Review
- Article
- The association of life's essential 8 with prevalence of chronic respiratory diseases in adults: insights from NHANES 2007-2018.BMC pulmonary medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is considered one of the leading causes of mortality. Cardiovascular comorbidities are diagnosed often in COPD patients, not only because of the common risk factors these two diseases share, but also because of the systemic inflammation which characterizes COPD and has deleterious effects in the cardiovascular system. The comorbid cardiovascular diseases in COPD result in several difficulties in the holistic treatment of these patients and affect outcomes such as morbidity and mortality. Several studies have reported that mortality from cardiovascular causes is common among COPD patients, while the risk for acute cardiovascular events increases during COPD exacerbations and remains high for a long time even after recovery. In this review, we focus on the prevalence of cardiovascular comorbidities in COPD patients, presenting the evidence regarding the interaction of the pathophysiological pathways which characterize each disease. Furthermore, we summarize information regarding the effects of cardiovascular treatment on COPD outcomes and vice versa. Finally, we present the current evidence regarding the impact of cardiovascular comorbidities on exacerbations, quality of life and survival of COPD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.